Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corp プロフィール



企業コードEW

会社名Edwards Lifesciences Corp

上場日Mar 27, 2000

最高経営責任者「CEO」Zovighian (Bernard J)

従業員数15800

証券種類Ordinary Share

決算期末Mar 27

本社所在地One Edwards Way

都市IRVINE

証券取引所NASDAQ OMX NASDAQ Basic NYSE

国United States of America

郵便番号92614

電話番号19492502500

ウェブサイトhttps://www.edwards.com

企業コードEW

上場日Mar 27, 2000

最高経営責任者「CEO」Zovighian (Bernard J)

Edwards Lifesciences Corpの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

284.40K

+2.48%

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

29.80K

-1.07%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

29.80K

-1.07%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart (SURG) and Implantable Heart Failure Management (IHFM)

22.22K

-1.79%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

284.40K

+2.48%

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Ms. Theodora (Doretta) Mistras

Corporate Vice President, Chief Financial Officer

99.92K

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Steven R. (Steve) Loranger

Independent Director

79.69K

+5.41%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

39.29K

よくある質問

Edwards Lifesciences Corpの上位5名の株主は誰ですか？



Edwards Lifesciences Corpの上位5名の株主は以下のとおりです。Mr. Scott B. Ullem

Edwards Lifesciences Corp（EW）の株式を保有している機関の数はいくつですか？



2026Q1時点で、Edwards Lifesciences Corpの株式を保有している機関は2620社あり、保有株式の総市場価値は約539.60Mで、全体の93.71%を占めています。2025Q4と比較して、機関の持ち株は-12944884.00増加しています。

Edwards Lifesciences Corpの最大の収益源は何ですか？



2026Q1において、Transcatheter Aortic Valve Replacement部門がEdwards Lifesciences Corpにとって最大の収益を生み出しており、その金額は1.26Bで、全収益の72.27%を占めています。